Management of Small Nonfunctioning Pancreatic Neuroendocrine Neoplasms: Current Opinion and Controversies
Abstract
1. Introduction
2. Malignant Potential of Small PNENs
2.1. Tumor Size
Risk of Lymph Node Metastasis
2.2. Tumor Grade
2.3. Tumor Biomarker
3. Management of Small NF PNENs
3.1. Close Follow-Up
3.2. Surgery
Lymph Node Dissection
3.3. EUS-Guided Treatment
3.4. Follow-Up of Patients with PNENs
4. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Franko, J.; Feng, W.; Yip, L.; Genovese, E.; Moser, A.J. Non-functional neuroendocrine carcinoma of the pancreas: Incidence, tumor biology, and outcomes in 2158 patients. J. Gastrointest. Surg. 2010, 14, 541–548. [Google Scholar] [CrossRef] [PubMed]
- Khashab, M.A.; Yong, E.; Lennon, A.M.; Shin, E.J.; Amateau, S.; Hruban, R.H.; Olino, K.; Giday, S.; Fishman, E.K.; Wolfgang, C.L.; et al. EUS is still superior to multidetector computerized tomography for detection of pancreatic neuroendocrine tumors. Gastrointest. Endosc. 2011, 73, 691–696. [Google Scholar] [CrossRef] [PubMed]
- Oberg, K. Pancreatic endocrine tumors. Semin. Oncol. 2010, 37, 594–618. [Google Scholar] [CrossRef] [PubMed]
- Halfdanarson, T.R.; Rabe, K.G.; Rubin, J.; Petersen, G.M. Pancreatic neuroendocrine tumors (PNETs): Incidence, prognosis and recent trend toward improved survival. Ann. Oncol. 2008, 19, 1727–1733. [Google Scholar] [CrossRef] [PubMed]
- Kloppel, G.; Rindi, G.; Perren, A.; Komminoth, P.; Klimstra, D.S. The ENETS and AJCC/UICC TNM classifications of the neuroendocrine tumors of the gastrointestinal tract and the pancreas: A statement. Virchows Arch. 2010, 456, 595–597. [Google Scholar] [CrossRef] [PubMed]
- Plockinger, U.; Rindi, G.; Arnold, R.; Eriksson, B.; Krenning, E.P.; de Herder, W.W.; Goede, A.; Caplin, M.; Oberg, K.; Reubi, J.C.; et al. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology 2004, 80, 394–424. [Google Scholar] [CrossRef]
- Rindi, G.; Kloppel, G.; Couvelard, A.; Komminoth, P.; Korner, M.; Lopes, J.M.; McNicol, A.M.; Nilsson, O.; Perren, A.; Scarpa, A.; et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: A consensus proposal including a grading system. Virchows Arch. 2007, 451, 757–762. [Google Scholar] [CrossRef]
- Cho, J.H.; Ryu, J.K.; Song, S.Y.; Hwang, J.H.; Lee, D.K.; Woo, S.M.; Joo, Y.E.; Jeong, S.; Lee, S.O.; Park, B.K.; et al. Prognostic validity of the american joint committee on cancer and the european neuroendocrine tumors staging classifications for pancreatic neuroendocrine tumors: A retrospective nationwide multicenter study in south korea. Pancreas 2016, 45, 941–946. [Google Scholar] [CrossRef]
- Han, X.; Xu, X.; Ma, H.; Ji, Y.; Wang, D.; Kuang, T.; Wu, W.; Song, B.; Li, G.; Jin, G.; et al. Clinical relevance of different WHO grade 3 pancreatic neuroendocrine neoplasms based on morphology. Endocr. Connect. 2018, 7, 355–363. [Google Scholar] [CrossRef]
- Rindi, G.; Mete, O.; Uccella, S.; Basturk, O.; La Rosa, S.; Brosens, L.A.A.; Ezzat, S.; de Herder, W.W.; Klimstra, D.S.; Papotti, M.; et al. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Endocr. Pathol. 2022, 33, 115–154. [Google Scholar] [CrossRef]
- Bettini, R.; Partelli, S.; Boninsegna, L.; Capelli, P.; Crippa, S.; Pederzoli, P.; Scarpa, A.; Falconi, M. Tumor size correlates with malignancy in nonfunctioning pancreatic endocrine tumor. Surgery 2011, 150, 75–82. [Google Scholar] [CrossRef] [PubMed]
- Falconi, M.; Bartsch, D.K.; Eriksson, B.; Kloppel, G.; Lopes, J.M.; O’Connor, J.M.; Salazar, R.; Taal, B.G.; Vullierme, M.P.; O’Toole, D.; et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: Well-differentiated pancreatic non-functioning tumors. Neuroendocrinology 2012, 95, 120–134. [Google Scholar] [CrossRef] [PubMed]
- Paik, W.H.; Lee, H.S.; Lee, K.J.; Jang, S.I.; Lee, W.J.; Hwang, J.H.; Cho, C.M.; Park, C.H.; Han, J.; Woo, S.M.; et al. Malignant potential of small pancreatic neuroendocrine neoplasm and its risk factors: A multicenter nationwide study. Pancreatology 2021, 21, 208–214. [Google Scholar] [CrossRef] [PubMed]
- Kurita, Y.; Hara, K.; Kuwahara, T.; Mizuno, N.; Okuno, N.; Haba, S.; Okuno, M.; Natsume, S.; Senda, Y.; Kubota, K.; et al. Comparison of prognosis between observation and surgical resection groups with small sporadic non-functional pancreatic neuroendocrine neoplasms without distant metastasis. J. Gastroenterol. 2020, 55, 543–552. [Google Scholar] [CrossRef]
- Jung, J.G.; Lee, K.T.; Woo, Y.S.; Lee, J.K.; Lee, K.H.; Jang, K.T.; Rhee, J.C. Behavior of Small, Asymptomatic, Nonfunctioning Pancreatic Neuroendocrine Tumors (NF-PNETs). Medicine 2015, 94, e983. [Google Scholar] [CrossRef] [PubMed]
- Kishi, Y.; Shimada, K.; Nara, S.; Esaki, M.; Hiraoka, N.; Kosuge, T. Basing treatment strategy for non-functional pancreatic neuroendocrine tumors on tumor size. Ann. Surg. Oncol. 2014, 21, 2882–2888. [Google Scholar] [CrossRef] [PubMed]
- Yang, G.; Ji, M.; Chen, J.; Chen, R.; Chen, Y.; Fu, D.; Hou, B.; Huang, H.; Jiang, L.; Jin, K.; et al. Surgery management for sporadic small (≤2 cm), non-functioning pancreatic neuroendocrine tumors: A consensus statement by the Chinese Study Group for Neuroendocrine Tumors (CSNET). Int. J. Oncol. 2017, 50, 567–574. [Google Scholar] [CrossRef]
- Regenet, N.; Carrere, N.; Boulanger, G.; de Calan, L.; Humeau, M.; Arnault, V.; Kraimps, J.L.; Mathonnet, M.; Pessaux, P.; Donatini, G.; et al. Is the 2-cm size cutoff relevant for small nonfunctioning pancreatic neuroendocrine tumors: A French multicenter study. Surgery 2016, 159, 901–907. [Google Scholar] [CrossRef]
- Perinel, J.; Nappo, G.; Zerbi, A.; Heidsma, C.M.; Nieveen van Dijkum, E.J.M.; Han, H.S.; Yoon, Y.S.; Satoi, S.; Demir, I.E.; Friess, H.; et al. Sporadic nonfunctional pancreatic neuroendocrine tumors: Risk of lymph node metastases and aggressiveness according to tumor size: A multicenter international study. Surgery 2022, 172, 975–981. [Google Scholar] [CrossRef]
- Kuo, E.J.; Salem, R.R. Population-level analysis of pancreatic neuroendocrine tumors 2 cm or less in size. Ann. Surg. Oncol. 2013, 20, 2815–2821. [Google Scholar] [CrossRef]
- Gratian, L.; Pura, J.; Dinan, M.; Roman, S.; Reed, S.; Sosa, J.A. Impact of extent of surgery on survival in patients with small nonfunctional pancreatic neuroendocrine tumors in the United States. Ann. Surg. Oncol. 2014, 21, 3515–3521. [Google Scholar] [CrossRef] [PubMed]
- Sallinen, V.J.; Le Large, T.Y.S.; Tieftrunk, E.; Galeev, S.; Kovalenko, Z.; Haugvik, S.P.; Antila, A.; Franklin, O.; Martinez-Moneo, E.; Robinson, S.M.; et al. Prognosis of sporadic resected small (≤2 cm) nonfunctional pancreatic neuroendocrine tumors—A multi-institutional study. HPB 2018, 20, 251–259. [Google Scholar] [CrossRef] [PubMed]
- Lee, K.J.; Cho, J.H.; Lee, S.H.; Song, S.Y.; Lee, K.H.; Jeong, S.; Ryu, J.K.; Woo, S.M.; Bang, S.; Lee, J.K.; et al. Clinical outcomes of everolimus in patients with advanced, nonfunctioning pancreatic neuroendocrine tumors: A multicenter study in Korea. Cancer Chemother. Pharmacol. 2017, 80, 799–805. [Google Scholar] [CrossRef] [PubMed]
- Martin-Perez, E.; Capdevila, J.; Castellano, D.; Jimenez-Fonseca, P.; Salazar, R.; Beguiristain-Gomez, A.; Alonso-Orduna, V.; Martinez Del Prado, P.; Villabona-Artero, C.; Diaz-Perez, J.A.; et al. Prognostic factors and long-term outcome of pancreatic neuroendocrine neoplasms: Ki-67 index shows a greater impact on survival than disease stage. The large experience of the Spanish National Tumor Registry (RGETNE). Neuroendocrinology 2013, 98, 156–168. [Google Scholar] [CrossRef] [PubMed]
- Garcia-Carbonero, R.; Sorbye, H.; Baudin, E.; Raymond, E.; Wiedenmann, B.; Niederle, B.; Sedlackova, E.; Toumpanakis, C.; Anlauf, M.; Cwikla, J.B.; et al. ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas. Neuroendocrinology 2016, 103, 186–194. [Google Scholar] [CrossRef]
- Larghi, A.; Capurso, G.; Carnuccio, A.; Ricci, R.; Alfieri, S.; Galasso, D.; Lugli, F.; Bianchi, A.; Panzuto, F.; De Marinis, L.; et al. Ki-67 grading of nonfunctioning pancreatic neuroendocrine tumors on histologic samples obtained by EUS-guided fine-needle tissue acquisition: A prospective study. Gastrointest. Endosc. 2012, 76, 570–577. [Google Scholar] [CrossRef]
- Hasegawa, T.; Yamao, K.; Hijioka, S.; Bhatia, V.; Mizuno, N.; Hara, K.; Imaoka, H.; Niwa, Y.; Tajika, M.; Kondo, S.; et al. Evaluation of Ki-67 index in EUS-FNA specimens for the assessment of malignancy risk in pancreatic neuroendocrine tumors. Endoscopy 2014, 46, 32–38. [Google Scholar] [CrossRef]
- Howe, J.R.; Merchant, N.B.; Conrad, C.; Keutgen, X.M.; Hallet, J.; Drebin, J.A.; Minter, R.M.; Lairmore, T.C.; Tseng, J.F.; Zeh, H.J.; et al. The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors. Pancreas 2020, 49, 1–33. [Google Scholar] [CrossRef]
- Boutsen, L.; Jouret-Mourin, A.; Borbath, I.; van Maanen, A.; Weynand, B. Accuracy of Pancreatic Neuroendocrine Tumour Grading by Endoscopic Ultrasound-Guided Fine Needle Aspiration: Analysis of a Large Cohort and Perspectives for Improvement. Neuroendocrinology 2018, 106, 158–166. [Google Scholar] [CrossRef]
- Mizumoto, T.; Toyama, H.; Terai, S.; Mukubou, H.; Yamashita, H.; Shirakawa, S.; Nanno, Y.; Sofue, K.; Kido, M.; Ajiki, T.; et al. Prediction of lymph node metastasis in pancreatic neuroendocrine tumors by contrast enhancement characteristics. Pancreatology 2017, 17, 956–961. [Google Scholar] [CrossRef]
- Takumi, K.; Fukukura, Y.; Higashi, M.; Ideue, J.; Umanodan, T.; Hakamada, H.; Kanetsuki, I.; Yoshiura, T. Pancreatic neuroendocrine tumors: Correlation between the contrast-enhanced computed tomography features and the pathological tumor grade. Eur. J. Radiol. 2015, 84, 1436–1443. [Google Scholar] [CrossRef] [PubMed]
- Hyodo, R.; Suzuki, K.; Ogawa, H.; Komada, T.; Naganawa, S. Pancreatic neuroendocrine tumors containing areas of iso- or hypoattenuation in dynamic contrast-enhanced computed tomography: Spectrum of imaging findings and pathological grading. Eur. J. Radiol. 2015, 84, 2103–2109. [Google Scholar] [CrossRef] [PubMed]
- Nanno, Y.; Matsumoto, I.; Zen, Y.; Otani, K.; Uemura, J.; Toyama, H.; Asari, S.; Goto, T.; Ajiki, T.; Okano, K.; et al. Pancreatic Duct Involvement in Well-Differentiated Neuroendocrine Tumors is an Independent Poor Prognostic Factor. Ann. Surg. Oncol. 2017, 24, 1127–1133. [Google Scholar] [CrossRef] [PubMed]
- Mintziras, I.; Keck, T.; Werner, J.; Fichtner-Feigl, S.; Wittel, U.; Senninger, N.; Vowinkel, T.; Koninger, J.; Anthuber, M.; Geissler, B.; et al. Implementation of Current ENETS Guidelines for Surgery of Small (≤2 cm) Pancreatic Neuroendocrine Neoplasms in the German Surgical Community: An Analysis of the Prospective DGAV StuDoQ|Pancreas Registry. World J. Surg. 2019, 43, 175–182. [Google Scholar] [CrossRef]
- Campana, D.; Nori, F.; Piscitelli, L.; Morselli-Labate, A.M.; Pezzilli, R.; Corinaldesi, R.; Tomassetti, P. Chromogranin A: Is it a useful marker of neuroendocrine tumors? J. Clin. Oncol. 2007, 25, 1967–1973. [Google Scholar] [CrossRef]
- Kanakis, G.; Kaltsas, G. Biochemical markers for gastroenteropancreatic neuroendocrine tumours (GEP-NETs). Best Pract. Res. Clin. Gastroenterol. 2012, 26, 791–802. [Google Scholar] [CrossRef]
- Hofland, J.; Zandee, W.T.; de Herder, W.W. Role of biomarker tests for diagnosis of neuroendocrine tumours. Nat. Rev. Endocrinol. 2018, 14, 656–669. [Google Scholar] [CrossRef]
- Modlin, I.M.; Bodei, L.; Kidd, M. Neuroendocrine tumor biomarkers: From monoanalytes to transcripts and algorithms. Best Pract. Res. Clin. Endocrinol. Metab. 2016, 30, 59–77. [Google Scholar] [CrossRef]
- Wang, Y.H.; Yang, Q.C.; Lin, Y.; Xue, L.; Chen, M.H.; Chen, J. Chromogranin A as a marker for diagnosis, treatment, and survival in patients with gastroenteropancreatic neuroendocrine neoplasm. Medicine 2014, 93, e247. [Google Scholar] [CrossRef]
- Raoof, M.; Jutric, Z.; Melstrom, L.G.; Lee, B.; Li, D.; Warner, S.G.; Fong, Y.; Singh, G. Prognostic significance of Chromogranin A in small pancreatic neuroendocrine tumors. Surgery 2019, 165, 760–766. [Google Scholar] [CrossRef]
- Calabro, D.; Argalia, G.; Ambrosini, V. Role of PET/CT and Therapy Management of Pancreatic Neuroendocrine Tumors. Diagnostics 2020, 10, 1059. [Google Scholar] [CrossRef] [PubMed]
- Eychenne, R.; Bouvry, C.; Bourgeois, M.; Loyer, P.; Benoist, E.; Lepareur, N. Overview of Radiolabeled Somatostatin Analogs for Cancer Imaging and Therapy. Molecules 2020, 25, 4012. [Google Scholar] [CrossRef] [PubMed]
- Pavel, M.; Oberg, K.; Falconi, M.; Krenning, E.P.; Sundin, A.; Perren, A.; Berruti, A. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2020, 31, 844–860. [Google Scholar] [CrossRef] [PubMed]
- Prosperi, D.; Gentiloni Silveri, G.; Panzuto, F.; Faggiano, A.; Russo, V.M.; Caruso, D.; Polici, M.; Lauri, C.; Filice, A.; Laghi, A.; et al. Nuclear Medicine and Radiological Imaging of Pancreatic Neuroendocrine Neoplasms: A Multidisciplinary Update. J. Clin. Med. 2022, 11, 6836. [Google Scholar] [CrossRef]
- Massironi, S.; Rossi, R.E.; Zilli, A.; Casazza, G.; Ciafardini, C.; Conte, D. A wait-and-watch approach to small pancreatic neuroendocrine tumors: Prognosis and survival. Oncotarget 2016, 7, 18978–18983. [Google Scholar] [CrossRef] [PubMed]
- Sallinen, V.; Le Large, T.Y.; Galeev, S.; Kovalenko, Z.; Tieftrunk, E.; Araujo, R.; Ceyhan, G.O.; Gaujoux, S. Surveillance strategy for small asymptomatic non-functional pancreatic neuroendocrine tumors—A systematic review and meta-analysis. HPB 2017, 19, 310–320. [Google Scholar] [CrossRef]
- Barenboim, A.; Lahat, G.; Nachmany, I.; Nakache, R.; Goykhman, Y.; Geva, R.; Osher, E.; Scapa, E.; Wolf, I.; Orbach, L.; et al. Resection Versus Observation of Small Asymptomatic Nonfunctioning Pancreatic Neuroendocrine Tumors. J. Gastrointest. Surg. 2020, 24, 1366–1374. [Google Scholar] [CrossRef]
- Sharpe, S.M.; In, H.; Winchester, D.J.; Talamonti, M.S.; Baker, M.S. Surgical resection provides an overall survival benefit for patients with small pancreatic neuroendocrine tumors. J. Gastrointest. Surg. 2015, 19, 117–123. [Google Scholar] [CrossRef]
- Finkelstein, P.; Sharma, R.; Picado, O.; Gadde, R.; Stuart, H.; Ripat, C.; Livingstone, A.S.; Sleeman, D.; Merchant, N.; Yakoub, D. Pancreatic Neuroendocrine Tumors (panNETs): Analysis of Overall Survival of Nonsurgical Management Versus Surgical Resection. J. Gastrointest. Surg. 2017, 21, 855–866. [Google Scholar] [CrossRef]
- Zhu, J.; Fu, C.; Zhang, Y.; Zhou, X.; Xiao, W.; Li, Y. Observation Versus Resection for Small, Localized, and Nonfunctional Pancreatic Neuroendocrine Tumors: A Propensity Score Matching Study. Pancreas 2022, 51, 56–62. [Google Scholar] [CrossRef]
- Beane, J.D.; Borrebach, J.D.; Billderback, A.; Onuma, A.E.; Adam, M.A.; Zureikat, A.H.; Pitt, H.A. Small pancreatic neuroendocrine tumors: Resect or enucleate? Am. J. Surg. 2021, 222, 29–34. [Google Scholar] [CrossRef] [PubMed]
- Shah, M.H.; Goldner, W.S.; Benson, A.B.; Bergsland, E.; Blaszkowsky, L.S.; Brock, P.; Chan, J.; Das, S.; Dickson, P.V.; Fanta, P.; et al. Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Canc. Netw. 2021, 19, 839–868. [Google Scholar] [CrossRef] [PubMed]
- Guo, N.; Liang, Z.; Xiong, L.J. Clinicopathological characteristics, survival outcomes and prognostic factors in the cT1N0M0 pancreatic neuroendocrine tumors: A SEER-based study. Medicine 2022, 101, e31019. [Google Scholar] [CrossRef] [PubMed]
- Paik, W.H.; Seo, D.W.; Dhir, V.; Wang, H.P. Safety and efficacy of eus-guided ethanol ablation for treating small solid pancreatic neoplasm. Medicine 2016, 95, e2538. [Google Scholar] [CrossRef]
- Rimbas, M.; Horumba, M.; Rizzatti, G.; Crino, S.F.; Gasbarrini, A.; Costamagna, G.; Larghi, A. Interventional endoscopic ultrasound for pancreatic neuroendocrine neoplasms. Dig. Endosc. 2020, 32, 1031–1041. [Google Scholar] [CrossRef]
- Imperatore, N.; de Nucci, G.; Mandelli, E.D.; de Leone, A.; Zito, F.P.; Lombardi, G.; Manes, G. Endoscopic ultrasound-guided radiofrequency ablation of pancreatic neuroendocrine tumors: A systematic review of the literature. Endosc. Int. Open 2020, 8, E1759–E1764. [Google Scholar] [CrossRef]
- Choi, J.H.; Seo, D.W.; Song, T.J.; Park, D.H.; Lee, S.S.; Lee, S.K.; Kim, M.H. Endoscopic ultrasound-guided radiofrequency ablation for management of benign solid pancreatic tumors. Endoscopy 2018, 50, 1099–1104. [Google Scholar]
- Lakhtakia, S.; Ramchandani, M.; Galasso, D.; Gupta, R.; Venugopal, S.; Kalpala, R.; Reddy, D.N. Eus-guided radiofrequency ablation for management of pancreatic insulinoma by using a novel needle electrode (with videos). Gastrointest. Endosc. 2016, 83, 234–239. [Google Scholar] [CrossRef]
- Oleinikov, K.; Dancour, A.; Epshtein, J.; Benson, A.; Mazeh, H.; Tal, I.; Matalon, S.; Benbassat, C.A.; Livovsky, D.M.; Goldin, E.; et al. Endoscopic ultrasound-guided radiofrequency ablation: A new therapeutic approach for pancreatic neuroendocrine tumors. J. Clin. Endocrinol. Metab. 2019, 104, 2637–2647. [Google Scholar] [CrossRef]
- Younis, F.; Ben-Ami Shor, D.; Lubezky, N.; Geva, R.; Osher, E.; Shibolet, O.; Phillips, A.; Scapa, E. Endoscopic ultrasound-guided radiofrequency ablation of premalignant pancreatic-cystic neoplasms and neuroendocrine tumors: Prospective study. Eur. J. Gastroenterol. Hepatol. 2022, 34, 1111–1115. [Google Scholar] [CrossRef]
- So, H.; Ko, S.W.; Shin, S.H.; Kim, E.H.; Son, J.; Ha, S.; Song, K.B.; Kim, H.J.; Kim, M.H.; Park, D.H. Comparison of EUS-guided ablation and surgical resection for non-functioning small pancreatic neuroendocrine tumors: A propensity score matching study. Gastrointest. Endosc. 2022; in press. [Google Scholar] [CrossRef] [PubMed]
- Clark, O.H.; Benson, A.B., 3rd; Berlin, J.D.; Choti, M.A.; Doherty, G.M.; Engstrom, P.F.; Gibbs, J.F.; Heslin, M.J.; Kessinger, A.; Kulke, M.H.; et al. NCCN Clinical Practice Guidelines in Oncology: Neuroendocrine tumors. J. Natl. Compr. Canc. Netw. 2009, 7, 712–747. [Google Scholar] [CrossRef] [PubMed]
NET-G1 | NET-G2 | NET-G3 | NEC-G3 |
---|---|---|---|
Well-differentiated Mitotic count < 2/2 mm2 Ki-67 ≤ 2% | Well-differentiated Mitotic count < 2–20/2 mm2 Ki-67 3–20% | Well-differentiated Mitotic count > 20/2 mm2 Ki-67 > 20% | Poorly differentiated Mitotic count > 20/2 mm2 Ki-67 > 20% |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Paik, W.H.; Lee, K.J. Management of Small Nonfunctioning Pancreatic Neuroendocrine Neoplasms: Current Opinion and Controversies. J. Clin. Med. 2023, 12, 251. https://doi.org/10.3390/jcm12010251
Paik WH, Lee KJ. Management of Small Nonfunctioning Pancreatic Neuroendocrine Neoplasms: Current Opinion and Controversies. Journal of Clinical Medicine. 2023; 12(1):251. https://doi.org/10.3390/jcm12010251
Chicago/Turabian StylePaik, Woo Hyun, and Kyong Joo Lee. 2023. "Management of Small Nonfunctioning Pancreatic Neuroendocrine Neoplasms: Current Opinion and Controversies" Journal of Clinical Medicine 12, no. 1: 251. https://doi.org/10.3390/jcm12010251
APA StylePaik, W. H., & Lee, K. J. (2023). Management of Small Nonfunctioning Pancreatic Neuroendocrine Neoplasms: Current Opinion and Controversies. Journal of Clinical Medicine, 12(1), 251. https://doi.org/10.3390/jcm12010251